Obesity is a complex, chronic disease and global public health challenge. Characterized by
excessive fat accumulation in the body, obesity sharply increases the risk of several …

The gastrointestinal tract plays a role in the development and treatment of metabolic
diseases. During a meal, the gut provides crucial information to the brain regarding …

Background The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad
pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose …

Objective A novel dual GIP and GLP-1 receptor agonist, LY3298176, was developed to
determine whether the metabolic action of GIP adds to the established clinical benefits of …

The efficacy of Roux-en-Y gastric-bypass (RYGB) and other bariatric surgeries in the
management of obesity and type 2 diabetes mellitus and novel developments in …

Gut intraepithelial lymphocytes (IELs) are thought to calibrate glucagon-like peptide 1 (GLP-
1) bioavailability, thereby regulating systemic glucose and lipid metabolism. Here, we show …

Background Specialized endoderm‐derived epithelial cells, that is, enteroendocrine cells
(EEC s), are widely distributed throughout the gastrointestinal (GI) tract. Enteroendocrine …

In healthy humans, the incretin glucagon-like peptide 1 (GLP-1) is secreted after eating and
lowers glucose concentrations by augmenting insulin secretion and suppressing glucagon …

The preproglucagon gene (Gcg) is expressed by specific enteroendocrine cells (L-cells) of
the intestinal mucosa, pancreatic islet α-cells, and a discrete set of neurons within the …

Obesity is reaching epidemic proportions globally and represents a major cause of
comorbidities, mostly related to cardiovascular disease. The autonomic nervous system …